Address
Email address
Phone number
Website
Elite erakliinik Tartus Sangla 63. Viljatusravi ja günekoloogid, 3D-4D ultraheli, endokrinoloog, nahaarstid, kõrva-nina-kurguarstid, onkoloogid jpm. erialad
Name
OÜ Tähe Erakliinik
Registry code
10911949
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
18.12.2002 (21)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
86221 - Provision of specialised medical treatment
259 272 €
86 718 €
33%
2 805 €
(estimate is approximate)
425 047 €
3
Submitted
No tax arrears
20%
19%
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Andrei Sõritsa 25.11.1961 (62) | 100% - 2 556.00 EUR | Board member | Direct ownership | Founder |
Deniss Sõritsa 16.11.1982 (42) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member |
2019 29.06.2020 | 2020 30.06.2021 | 2021 28.06.2022 | 2022 29.06.2023 | 2023 28.06.2024 | |
---|---|---|---|---|---|
Total Revenue | 95 575 € | 73 436 € | 87 158 € | 172 963 € | 259 272 € |
Net profit (loss) for the period | -1 654 € | -425 € | 898 € | 54 544 € | 86 718 € |
Profit Margin | -2% | -1% | 1% | 32% | 33% |
Current Assets | 204 096 € | 23 804 € | 41 280 € | 132 242 € | 52 864 € |
Fixed Assets | 87 000 € | 267 593 € | 254 274 € | 222 629 € | 392 751 € |
Total Assets | 291 096 € | 291 397 € | 295 554 € | 354 871 € | 445 615 € |
Current Liabilities | 7 724 € | 8 450 € | 11 709 € | 16 482 € | 20 568 € |
Non Current Liabilities | - | - | - | - | - |
Total Liabilities | - | - | - | - | - |
Share Capital | - | - | - | - | - |
Equity | 283 372 € | 282 947 € | 283 845 € | 338 389 € | 425 047 € |
Employees | 2 | 2 | 1 | 2 | 3 |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q1 | - | 15 029.02 € | 15 781.78 € | 11 |
2023 Q4 | - | 13 444.6 € | 14 129.77 € | 11 |
2023 Q3 | - | 9 496.16 € | 9 951.64 € | 11 |
2023 Q2 | - | 14 149.95 € | 14 746.8 € | 12 |
2023 Q1 | - | 11 355.55 € | 11 809.31 € | 13 |
2022 Q4 | - | 8 625.09 € | 8 963.13 € | 13 |
2022 Q3 | - | 6 781.47 € | 7 029.99 € | 8 |
2022 Q2 | - | 5 768.67 € | 6 000.79 € | 8 |
2022 Q1 | - | 6 092.86 € | 6 339.93 € | 8 |
2021 Q4 | - | 4 404.9 € | 4 619.51 € | 8 |
2021 Q3 | - | 3 656.62 € | 3 833.13 € | 7 |
2021 Q2 | - | 3 452.03 € | 3 622.83 € | 7 |
2021 Q1 | - | 3 066.63 € | 3 212.77 € | 7 |
2020 Q4 | - | 2 655.29 € | 2 773.26 € | 8 |
2020 Q3 | - | 2 230.96 € | 2 315.96 € | 7 |
2020 Q2 | - | 2 440.24 € | 2 499.8 € | 5 |
2020 Q1 | - | 3 056.52 € | 3 134.89 € | 4 |